Cochlear's first-of-its-kind hybrid device gets regulatory approval in US
25 March, 2014After the US FDA approved the first-of-its-kind hearing device, Cochlear has launched a new hybrid hearing solution that helps people's hearing by amplifying low-frequency hearing and restoring access to high-frequency hearing, and will open up new opportunities in the US market.
Cochlear cleared to sell new device in US
21 March, 2014 by Dylan Bushell-EmblingThe FDA has granted Cochlear (ASX:COH) approval to sell the Nucleus Hybrid L24 - a new cochlear implant system designed to address high-frequency hearing loss - in the US.
AusMedtech 2014 business matching now open
20 March, 2014The AusMedtech 2014 conference has re-introduced AusPartnering, a business matching and partnering platform allowing delegates to schedule 30-minute one-on-one meetings with other attendees in a dedicated meeting area. All conference attendees have access to the AusPartnering system upon registration.
New reference guide to agbiotech launched in Canberra
18 March, 2014The Agricultural Biotechnology Council of Australia (ABCA) today launched 'The Official Australian Reference Guide to Agricultural Biotechnology and GM Crops' to provide factual information about genetically modified crops based on scientific evidence and to provide a useful reference.
Mesoblast's new appointments "increase global visibility"
13 March, 2014 by Dylan Bushell-EmblingMesoblast's (ASX:MSB) hiring of a former Novartis CFO so soon after former Roche executive William Burns joined its board may help the company pursue international partnership deals, Bell Potter said.
Save the date for 'beaches, brains and biotech' at AusBiotech 2014 on the Gold Coast
13 March, 2014Wednesday 29 to Friday 31 October are the dates to save as the AusBiotech 2014 national conference heads for the Gold Coast at the Gold Coast Convention & Exhibition Centre.
CNS expands into UK, biometrics
12 March, 2014 by Dylan Bushell-EmblingBrisbane-based CRO CNS has opened a new office in London and launched a new biometrics service for its biotech industry customers.
Helping entrepreneurial students and recent graduates tap in
11 March, 2014Students and recent graduates with ideas in micro-, nano-, biotechnology or medical devices can apply for a grant to access an advanced technology co-working space.
China Summit paves the way for Australian companies
11 March, 2014Recognising the leading role China will take globally in the future of life sciences, AusBiotech recently presented the second Australia China Life Science Summit in Sydney and now continues to pave the way for Australian companies interested in opportunities in and with China.
Fibrotech completes phase Ia trial, moves to 1b
11 March, 2014 by Dylan Bushell-EmblingFibrotech said a phase Ia trial has demonstrated the safety of antifibrotic candidate FT011 in healthy volunteers, and revealed the company has started dosing for a phase IIb study.
Mesoblast appoints new director
10 March, 2014 by Dylan Bushell-EmblingMesoblast's new non-executive director, former Roche Pharmaceuticals CEO William Burns, is excited about the prospects for regenerative medicine.
Call for EOI to showcase SME medtech success
06 March, 2014Medical and Scientific Technologies Supplier Advocate Dr Greg Roger is seeking case studies to promote and raise awareness of the capabilities of Australian SMEs in the medical and scientific technology field, facilitate collaboration opportunities and share lessons learned.
PolyNovo gets US tick for NovoPore dressing
06 March, 2014 by Dylan Bushell-EmblingCalzada's (ASX:CZD) PolyNovo subsidiary has won 510(k) approval in the US for TNP foam dressing NovoPore, which has become the first approved product based on its NovoSorb technology.
Neuren well funded for clinical trials
05 March, 2014 by Dylan Bushell-EmblingNeuren's (ASX:NEU) cash balance of $25m should be enough to fund key clinical trials of neurological drug candidate NNZ-2566 through to the expected receipt of licensing revenue in 2015, Bell Potter says.
AusBiotech articulates support for tax reform
04 March, 2014Building on the strategic plan that was presented at the AusBiotech national conference in November by AusBiotech Chair Dr Deborah Rathjen, the organisation is continuing its call for further tax reform in Australia.
